๐ ๐๐๐ญ๐ข๐ง๐ ๐๐ฉ๐๐๐ญ๐ ๐ ๐ ๐๐๐๐ -๐๐๐ฌ๐๐ ๐๐ฒ๐ ๐๐ซ๐จ๐ฉ๐ฌ ๐๐ก๐จ๐ฐ ๐๐ซ๐จ๐ฆ๐ข๐ฌ๐...
๐๐๐ง๐ณ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐๐ซ๐ ๐๐ฌ ๐๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ข๐ญ๐ ๐๐ข๐จ
๐ ๐ค Four months following the initiation of a definitive merger agreement, LENZ Therapeutics and Graphite Bio have seamlessly amalgamated under a singular identity. With a primary focus on addressing presbyopia, Lenz Therapeutics aims to propel its ground breaking preservative-free, single-use, once-daily eye drops forward. These therapeutics candidates, LNZ199 (1.75% aceclidine) and LNZ101 (1.75% aceclidine and brimonidine), represent significant strides in presbyopia management. The merger signifies a concerted effort to advance research and development in the realm of presbyopia treatment, promising innovative solutions to enhance vision and quality of life for affected individuals.
